Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-Current Assets (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Non-Current Assets data on record, last reported at $5.2 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 53.59% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $24.2 million, down 42.35%, while the annual FY2024 figure was $6.9 million, 2.53% down from the prior year.
  • Non-Current Assets reached $5.2 million in Q3 2025 per RANI's latest filing, down from $5.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $12.1 million in Q1 2024 and bottomed at $4.6 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $7.3 million, with a median of $7.1 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: skyrocketed 63.91% in 2024, then tumbled 53.59% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $4.6 million in 2021, then surged by 54.01% to $7.1 million in 2022, then fell by 0.48% to $7.1 million in 2023, then decreased by 2.53% to $6.9 million in 2024, then fell by 24.76% to $5.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $5.2 million in Q3 2025, $5.8 million in Q2 2025, and $6.3 million in Q1 2025.